Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection.

Autor:	Manenti A; VisMederi Srl, Siena, Italy., Solfanelli N; VisMederi Srl, Siena, Italy., Cantaloni P; VisMederi Srl, Siena, Italy., Mazzini L; VisMederi Srl, Siena, Italy., Leonardi M; VisMederi Srl, Siena, Italy.; VisMederi Research Srl, Siena, Italy., Benincasa L; VisMederi Research Srl, Siena, Italy., Piccini G; VisMederi Srl, Siena, Italy., Marchi S; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy., Boncioli M; VisMederi Research Srl, Siena, Italy., Spertilli Raffaelli C; Department of Infectious Diseases, Ospedale San Donato, Arezzo, Italy., Tacconi D; Department of Infectious Diseases, Ospedale San Donato, Arezzo, Italy., Mattiuzzo G; Medicines and Healthcare Products Regulatory Agency, South Mimms, United Kingdom., Kistner O; VisMederi Srl, Siena, Italy., Montomoli E; VisMederi Srl, Siena, Italy.; VisMederi Research Srl, Siena, Italy.; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy., Trombetta CM; VisMederi Research Srl, Siena, Italy.; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in public health [Front Public Health] 2023 Jun 21; Vol. 11, pp. 1195674. Date of Electronic Publication: 2023 Jun 21 (Print Publication: 2023).
DOI:	10.3389/fpubh.2023.1195674
Abstrakt:	Introduction: In early to mid-2022, an unexpected outbreak of Monkeypox virus infections occurred outside the African endemic regions. Vaccines originally developed in the past to protect against smallpox are one of the available countermeasures to prevent and protect against Orthopoxvirus infections. To date, there are few studies on the cross-reactivity of neutralizing antibodies elicited by previous vaccinia virus-based vaccination and/or Monkeypox virus infection. The aim of this study was to evaluate a possible approach to performing Monkeypox and vaccinia live-virus microneutralization assays in which the read-out is based on the production of cytopathic effect in the cell monolayer. Methods: Given the complexity of Orthopoxviruses, the microneutralization assay was performed in such a way as to uncover a potential role of complement, with and without the addition of an external source of Baby Rabbit Complement. A set of human serum samples from individuals who had been naturally infected with Monkeypox virus and individuals who may have and not have undergone vaccinia virus vaccinations, was used to evaluate the performance, sensitivity, and specificity of the assay. Results and Conclusions: The results of the present study confirm the presence and cross-reactivity of antibodies elicited by vaccinia-based vaccines, which proved able to neutralize the Monkeypox virus in the presence of an external source of complement. Competing Interests: AM, NS, PC, LM, GP, and MB were employed by VisMederi srl. LB and ML were employed by VisMederi Research srl. EM was founder and chief scientific officer of VisMederi srl and VisMederi Research srl. CT was an external consultant of VisMederi Research srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Manenti, Solfanelli, Cantaloni, Mazzini, Leonardi, Benincasa, Piccini, Marchi, Boncioli, Spertilli Raffaelli, Tacconi, Mattiuzzo, Kistner, Montomoli and Trombetta.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu